{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:58:01Z","timestamp":1771657081576,"version":"3.50.1"},"reference-count":16,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,12,22]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>A man in his 50s presented with an ulcerative lesion within the left axillary fold that had progressively worsened over 18\u2009months. Biopsy revealed an ulcerative basal cell carcinoma (BCC), which was surgically managed. CT chest scans done 7\u2009months later assessed post-treatment of radiotherapy. This revealed pulmonary lesions, which were biopsy-proven metastatic BCC. Sonidegib, a hedgehog signalling inhibitor, was used for first-line treatment. Due to progressive disease, sonidegib was ceased. Cemiplimab, a checkpoint inhibitor, was used as second-line treatment based on a phase II trial demonstrating efficacy in the setting of metastatic BCC. CT reports were initially consistent with response but after 6\u2009months of cemiplimab treatment, repeat CT chest scans revealed a decrease in size of the previously cited pulmonary lesions.<\/jats:p>\n               <jats:p>This is a rare case of BCC metastases which has limited treatment options. This case provides insight of the patient experience on such treatment.<\/jats:p>","DOI":"10.1136\/bcr-2022-251700","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T11:00:39Z","timestamp":1672830039000},"page":"e251700","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Management of basal cell carcinoma with pulmonary metastasis"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4257-6919","authenticated-orcid":false,"given":"Samuel Achilles","family":"Fordham","sequence":"first","affiliation":[{"name":"Dermatology, Sunshine Coast University Hospital, Birtinya, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3762-7109","authenticated-orcid":false,"given":"Emily Ximin","family":"Shao","sequence":"additional","affiliation":[{"name":"Dermatology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leith","family":"Banney","sequence":"additional","affiliation":[{"name":"Dermatology, Sunshine Coast University Hospital, Birtinya, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Azer","sequence":"additional","affiliation":[{"name":"Oncology, Sunshine Coast University Hospital, Sunshine Coast, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Dettrick","sequence":"additional","affiliation":[{"name":"Sunshine Coast University Hospital, University of Sunshine Coast, Birtinya, Queensland, Australia"},{"name":"Pathology, Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"2025082712560512000_16.1.e251700.1","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4965","article-title":"Metastatic and locally aggressive BCC: current treatment options","volume":"9","author":"Casey","year":"2021","journal-title":"Clin Case Rep"},{"key":"2025082712560512000_16.1.e251700.2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5694\/mja17.00284","article-title":"The incidence and multiplicity rates of keratinocyte cancers in Australia","volume":"207","author":"Pandeya","year":"2017","journal-title":"Med J Aust"},{"key":"2025082712560512000_16.1.e251700.3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13555-018-0277-7","article-title":"Hedgehog pathway inhibitors and their utility in basal cell carcinoma: a comprehensive review of current evidence","volume":"9","author":"Tay","year":"2019","journal-title":"Dermatol Ther"},{"key":"2025082712560512000_16.1.e251700.4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/biomedicines8110449","article-title":"Basal cell carcinoma: from pathophysiology to novel therapeutic approaches","volume":"8","author":"Fania","year":"2020","journal-title":"Biomedicines"},{"key":"2025082712560512000_16.1.e251700.5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/biomedicines5040071","article-title":"Histology of non-melanoma skin cancers: an update","volume":"5","author":"Paolino","year":"2017","journal-title":"Biomedicines"},{"key":"2025082712560512000_16.1.e251700.6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025082712560512000_16.1.e251700.7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5021\/ad.2011.23.2.213","article-title":"Pulmonary metastasis of basal cell carcinoma","volume":"23","author":"Seo","year":"2011","journal-title":"Ann Dermatol"},{"key":"2025082712560512000_16.1.e251700.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8929745","article-title":"Metastatic basal cell carcinoma: a rare manifestation of a common disease","volume":"2017","author":"Piva de Freitas","year":"2017","journal-title":"Case Rep Med"},{"key":"2025082712560512000_16.1.e251700.9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/2229-5178.144520","article-title":"Metastatic basal cell carcinoma to the lungs: case report and review of literature","volume":"5","author":"Nongrum","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"2025082712560512000_16.1.e251700.10","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.2147\/OTT.S108171","article-title":"Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma","volume":"9","author":"Doan","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2025082712560512000_16.1.e251700.11","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211066147","article-title":"Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again","volume":"14","author":"Davis","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2025082712560512000_16.1.e251700.12","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3286-5"},{"key":"2025082712560512000_16.1.e251700.13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/bjd.18552","article-title":"Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind bolt study","volume":"182","author":"Dummer","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025082712560512000_16.1.e251700.14","unstructured":"Australian Therapeutic Goods Administration . Australian public assessment report for Odomzo. Woden, ACT Australian Government; 2019: 90. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-odomzo-191127.pdf [Accessed 08 May 2022]."},{"key":"2025082712560512000_16.1.e251700.15","unstructured":"Australian Therapeutic Goods Administration . Public ATRG summary of LIBTAYO Cemiplimab 350mg concentrate for solution for infusion. North Ryde BC, NSW Australian Government; 2020: 2. http:\/\/www.ebs.tga.gov.au\/servlet\/xmlmillr6?dbid=ebs\/PublicHTML\/pdfStore.nsf&docid=FBC2BBC2EBF112FBCA2587A6003CB1D2&agid=(PrintDetailsPublic)&actionid=1 [Accessed 22 Mar 2022]."},{"key":"2025082712560512000_16.1.e251700.16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000775"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:56:14Z","timestamp":1756324574000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,4]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/bcr-2022-251700"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251700","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}